Featured News
(Medscape Medical News) Feb 17, 2020 - For the first time, a clear cell renal cell carcinoma therapy targets a molecular driver of the cancer that was previously believed to be "undruggable," said investigator Toni Choueiri, MD,...
(MedPage Today) Feb 15, 2020 - Patients with cisplatin-ineligible advanced bladder cancer achieved durable objective responses with the combination of pembrolizumab (Keytruda) and a newly approved antibody-drug conjugate (ADC), new data...
(Dana-Farber) Feb 15, 2020 - Scientists report promising activity of a novel drug that targets a key molecular driver of clear cell renal cell carcinoma (ccRCC) in patients with metastatic disease.
Researchers from Dana-Farber Cancer...
(BMS) Feb 15, 2020 - Updated results from CheckMate -214 study show that more than 50% of patients treated with Opdivo plus Yervoy were alive at 42 months compared to 39% of patients treated with sunitinib.
Complete response rates, per...
(BMS) Feb 15, 2020 - Bristol-Myers Squibb Company today announced five-year follow-up results from the Phase 3 CheckMate -025 study, which continue to demonstrate that treatment with Opdivo (nivolumab) delivers superior overall survival...
(Seattle Genetics) Feb 11, 2020 - Seattle Genetics, Inc. and Astellas Pharma Inc. today announced updated results from the phase 1b/2 clinical trial EV-103 in previously untreated patients with locally advanced or metastatic urothelial...
(The ASCO Post) Feb 14, 2020 - According to results from a phase II trial presented by Johann S. de Bono, MD, PhD, and colleagues at the 2020 Genitourinary (GU) Cancers Symposium (Abstract 119), treatment with the poly (ADP-ribose)...
(2020 GU) Feb 13, 2020 - Research from the 2020 Genitourinary (GU) Cancers Symposium highlights innovative new approaches for treating bladder, kidney, and prostate cancers.
The studies will be presented at the Symposium, taking place...
(BioSpace) Feb 11, 2020 - The company and cabozantinib appear to be bouncing back, with promising Phase I results in prostate cancer with cabozantinib in combination with Genentech’s checkpoint inhibitor Tecentriq...
(Astellas) Feb 10, 2020 - Seattle Genetics, Inc. and Astellas Pharma Inc. today announced updated results from the phase 1b/2 clinical trial EV-103 in previously untreated patients with locally advanced or metastatic urothelial cancer who...
More News
(PMLiVE.com [UK]) Feb 17, 2020 - Bristol-Myers Squibb has unveiled long-term results for Opdivo in renal cell carcinoma, which demonstrated efficacy with and without CTLA4 blocker Yervoy.
(Medscape Medical News) Feb 14, 2020 - Practice-changing studies in cancer care are almost always the result of an improvement in efficacy that "moves the needle," usually in terms of progression-free or overall survival.
But here at...
(Medscape Medical News) Feb 17, 2020 - It seemed like a sensible measure for desperate times, but reducing the standard frequency of doses of bacille Calmette-Guérin (BCG; Merck) for the treatment of high-grade bladder cancer resulted in...
(MedPage Today) Feb 15, 2020 - Patients with cisplatin-ineligible advanced bladder cancer achieved durable objective responses with the combination of pembrolizumab (Keytruda) and a newly approved antibody-drug conjugate (ADC), new data...
(MedPage Today) Feb 17, 2020 - Pairing immunotherapy with stereotactic body radiation therapy (SBRT) produced mixed results in advanced renal cell carcinoma (RCC) in two preliminary trials reported here.
(MedPage Today) Feb 14, 2020 - Immediate treatment of limited metastatic recurrence of prostate cancer led to a fourfold improvement in the proportion of patients alive without androgen deprivation therapy (ADT) at 5 years, according to...
(MedPage Today) Feb 14, 2020 - More than a fourth of men with high-risk prostate cancer had lymph node or distant metastases missed by CT or MRI but detected by PET imaging targeting prostate specific membrane antigen (PSMA), a...
(Yahoo! Finance) Feb 15, 2020 - Mirati Therapeutics, Inc., a clinical stage targeted oncology company, today announced the presentation of initial data from an ongoing investigator sponsored Phase 1/2 clinical trial of sitravatinib in...
(Decipher) Feb 13, 2020 - Decipher Biosciences today announced that a Decipher GRID molecular subtyping signature, studied in patients from the phase III, randomized controlled trial, CHAARTED, successfully predicted which prostate cancer...
(Dana-Farber) Feb 15, 2020 - Scientists report promising activity of a novel drug that targets a key molecular driver of clear cell renal cell carcinoma (ccRCC) in patients with metastatic disease.
Researchers from Dana-Farber Cancer...
Follow @OBRTweets